Comparing two methods of anticoagulation in kidney treatment
Comparison of Regional Citrate Anticoagulation (RCA) and Regional Anticoagulation by Citrate-Free Decalcification in Renal (RACD) Replacement Therapy Using Sustained Low-Efficiency Dialysis
This study is testing whether using a citrate infusion or a calcium-free dialysate during kidney dialysis can help prevent complications and make treatment safer for patients with acute kidney injury.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 138 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Groupe Hospitalier Sud Ile-de-France Academic / other |
| Locations | 1 site (Melun) |
| Trial ID | NCT04968587 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of two different anticoagulation methods during Sustained Low-Efficiency Dialysis (SLED) for patients requiring renal replacement therapy. It compares the use of a 4% citrate infusion against a calcium-free dialysate to determine which method better prevents complications associated with blood contact in the extracorporeal circuit. The goal is to reduce risks and costs associated with anticoagulation in patients undergoing intermittent renal replacement therapy. The study aims to provide insights into safer and more efficient treatment options for acute kidney injury.
Who should consider this trial
Good fit: Ideal candidates for this study are patients requiring renal replacement therapy due to acute kidney injury.
Not a fit: Patients under 18 years old, pregnant women, or those with specific coagulation disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer and more cost-effective anticoagulation methods for patients undergoing renal replacement therapy.
How similar studies have performed: While there have been studies on anticoagulation methods in renal replacement therapy, this specific approach using a calcium-free dialysate is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patient requiring Renal replacement Therapy Exclusion Criteria: * Age \< 18 years * Pregnancy * Hypercalcemia ≥ 3 mmol/L. * Major under guardianship * Major deprived of freedom * Impossible to obtain free and informed consent * Presence of hemostasis or coagulation disorders: * Thrombocytopenia \< 30 G/L. * Curative anticoagulation. * Severe liver disease with Prothrombin rate \<30%. * Coagulation factor deficit. * Not registered to a social security system.
Where this trial is running
Melun
- Groupe Hospitalier Sud Ile-de-France — Melun, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.